secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001193125-25-241415
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha regains full rights to TSHA-102 for Rett syndrome after Astellas option expires
--------------------------------------------------------------------------------

- Regained full rights to lead TSHA-102 program after 2022 Option Agreement with Astellas expired.
- TSHA-102 has FDA Breakthrough Therapy designation; Part A REVEAL data showed 100% response rate on primary endpoint.
- REVEAL pivotal trial dosing of first patient scheduled this quarter; FDA alignment on protocol and SAP obtained.
- Unencumbered rights enable full strategic flexibility and optionality for Taysha.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525241415/0001193125-25-241415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525241415/d35488d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-241415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer